When I last wrote about LipoScience (NASDAQ:LPDX) in May, I pointed out that there was a reasonable chance that LabCorp (NYSE:LH)
could acquire the company. LipoScience has struggled mightily as a
public company, but the struggles have been related more to the
company's limited resources and not the value or quality of the
LipoProfile test. That prediction has come home to roost now, as LabCorp
announced that it will in fact be acquiring LipoScience.
This deal by no means rescues the call I made
on LipoScience back in my first piece on the company for Seeking Alpha,
as the premium paid by LabCorp only makes it an incrementally
less-lousy call. For LabCorp, though, this is a solid (albeit small)
tuck-in deal and the sort of acquisition that could produce some
worthwhile value down the road.
Please read more here:
LipoScience Rescues Some Value For Shareholders In A Sale To LabCorp
No comments:
Post a Comment